Hideyuki Ohshimo

1.6k total citations · 1 hit paper
17 papers, 1.4k citations indexed

About

Hideyuki Ohshimo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hideyuki Ohshimo has authored 17 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Hideyuki Ohshimo's work include Colorectal Cancer Treatments and Studies (13 papers), Cancer Treatment and Pharmacology (6 papers) and Gastric Cancer Management and Outcomes (5 papers). Hideyuki Ohshimo is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Cancer Treatment and Pharmacology (6 papers) and Gastric Cancer Management and Outcomes (5 papers). Hideyuki Ohshimo collaborates with scholars based in Japan and Spain. Hideyuki Ohshimo's co-authors include Masakazu Fukushima, Tetsuhiko Shirasaka, Toshiyuki Kato, Masahiro Yamaguchi, Kazuhiko Yonekura, Yuji Shimamoto, Tomohiro Emura, Norihiko Suzuki, Akio Fujioka and Hiroko Saito and has published in prestigious journals such as Cancer Chemotherapy and Pharmacology, International Journal of Oncology and International Journal of Molecular Medicine.

In The Last Decade

Hideyuki Ohshimo

17 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

1996 707 citations Tetsuhiko Shirasaka, Hideyuki Ohshimo et al. Anti-Cancer Drugs profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hideyuki Ohshimo Japan	13	1.0k	709	317	284	112	17	1.4k
Kazuhiko Yonekura Japan	15	764 0.8×	624 0.9×	296 0.9×	474 1.7×	139 1.2×	23	1.3k
D. J. Th. Wagener Netherlands	18	506 0.5×	401 0.6×	236 0.7×	311 1.1×	154 1.4×	57	1.1k
Yuji Shimamoto Japan	14	584 0.6×	413 0.6×	160 0.5×	346 1.2×	77 0.7×	19	947
M. E. Vega-Villegas Spain	9	951 1.0×	562 0.8×	274 0.9×	152 0.5×	106 0.9×	17	1.2k
Marie‐Pierre Galais France	14	784 0.8×	662 0.9×	434 1.4×	238 0.8×	173 1.5×	38	1.3k
J J Lokich United States	5	1.4k 1.4×	486 0.7×	363 1.1×	163 0.6×	106 0.9×	6	1.6k
Kanwal Raghav United States	19	568 0.6×	349 0.5×	369 1.2×	221 0.8×	199 1.8×	52	1.1k
N. Androulakis Greece	20	1.1k 1.1×	681 1.0×	182 0.6×	236 0.8×	290 2.6×	46	1.3k
B. Barón Belgium	17	649 0.6×	543 0.8×	356 1.1×	209 0.7×	105 0.9×	28	1.4k
H Niitani Japan	17	1.4k 1.4×	842 1.2×	171 0.5×	862 3.0×	99 0.9×	61	1.8k

Countries citing papers authored by Hideyuki Ohshimo

Since Specialization

Citations

This map shows the geographic impact of Hideyuki Ohshimo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideyuki Ohshimo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideyuki Ohshimo more than expected).

Fields of papers citing papers by Hideyuki Ohshimo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideyuki Ohshimo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideyuki Ohshimo. The network helps show where Hideyuki Ohshimo may publish in the future.

Co-authorship network of co-authors of Hideyuki Ohshimo

This figure shows the co-authorship network connecting the top 25 collaborators of Hideyuki Ohshimo. A scholar is included among the top collaborators of Hideyuki Ohshimo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideyuki Ohshimo. Hideyuki Ohshimo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Emura, Tomohiro, Norihiko Suzuki, Akio Fujioka, Hideyuki Ohshimo, & Masakazu Fukushima. (2005). Potentiation of the antitumor activity of α, α, α-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. International Journal of Oncology. 27(2). 449–55. 65 indexed citations

Takechi, Teiji, Hiroyuki Okabe, Kazumasa Ikeda, et al.. (2005). Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.. PubMed. 14(1). 33–9. 13 indexed citations

Emura, Tomohiro, Norihiko Suzuki, Masahiro Yamaguchi, Hideyuki Ohshimo, & Masakazu Fukushima. (2004). A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. International Journal of Oncology. 25(3). 571–8. 96 indexed citations

Emura, Tomohiro, Fumio Nakagawa, Akio Fujioka, Hideyuki Ohshimo, & Kenji Kitazato. (2004). Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model. Oncology Reports. 11(2). 381–7. 18 indexed citations

Emura, Tomohiro, Fumio Nakagawa, Akio Fujioka, et al.. (2004). An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. International Journal of Molecular Medicine. 13(2). 249–55. 71 indexed citations

Nukatsuka, Mamoru, Akio Fujioka, Fumio Nakagawa, Hideyuki Ohshimo, & Masakazu Fukushima. (2002). [Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung].. PubMed. 29(1). 95–101. 4 indexed citations

Shimamoto, Yuji, Akio Fujioka, Hiromi Kazuno, et al.. (2001). Antitumor Activity and Pharmacokinetics of TAS‐106, l‐(3‐C‐Ethynyl‐β‐D‐ribo‐pentofuranosyl)cytosine. Japanese Journal of Cancer Research. 92(3). 343–351. 19 indexed citations

Kato, Toshiyuki, Yuji Shimamoto, Junji Uchida, et al.. (2001). Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.. PubMed. 21(3B). 1705–12. 32 indexed citations

Fukushima, Masakazu, Yuji Shimamoto, Toshiyuki Kato, et al.. (1998). Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anti-Cancer Drugs. 9(9). 817–823. 43 indexed citations

10.

Fukushima, M, Hirofumi Satake, Junji Uchida, et al.. (1998). Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.. International Journal of Oncology. 13(4). 693–8. 95 indexed citations

11.

Kurihara, M, et al.. (1997). Effect of combination therapy with UFT plus cisplatin (UFTP) on the survival of mice in the experimental model for wide-spread metastasis in the peritoneal cavity of gastrointestinal cancer using colon 26 PMF-15 cells.. PubMed. 17(3C). 2217–20. 3 indexed citations

12.

Shirasaka, Tetsuhiko, Hideyuki Ohshimo, Masahiro Yamaguchi, et al.. (1996). Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs. 7(5). 548–557. 707 indexed citations breakdown →

13.

Shirasaka, Tetsuhiko, Yuji Shimamoto, Hideyuki Ohshimo, Hiroko Saito, & Masakazu Fukushima. (1993). Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemotherapy and Pharmacology. 32(3). 167–172. 127 indexed citations

14.

Shirasaka, Tetsuhiko, Yuji Shimamoto, Hideyuki Ohshimo, Akiko Kimura, & M Fukushima. (1991). [Mechanism for synergistic antitumor effect in the combination of 5-fluorouracil with cisplatin in vivo tumor models: from the view of biochemical modulation of 5-fluorouracil].. PubMed. 18(3). 403–9. 12 indexed citations

15.

Shirasaka, Tetsuhiko, M Fukushima, Yuji Shimamoto, et al.. (1990). [Metabolic characteristics and antitumor activity of BOF-A2, a new 5-fluorouracil derivative].. PubMed. 17(5). 1051–8. 5 indexed citations

16.

Fujii, Setsuro, Masakazu Fukushima, Yuji Shimamoto, et al.. (1989). Antitumor Activity of BOF‐A2, a New 5‐Fluorouracil Derivative. Japanese Journal of Cancer Research. 80(2). 173–181. 23 indexed citations

17.

Shimamoto, Yuji, et al.. (1989). Effects of the Plasma Concentration of 5‐Fluorouracil and the Duration of Continuous Venous Infusion of 5‐Fluorouracil with an Inhibitor of 5‐Fluorouracil Degradation on Yoshida Sarcomas in Rats. Japanese Journal of Cancer Research. 80(2). 167–172. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact